NO20022246L - Behandling av subnormal benmineraltetthet - Google Patents

Behandling av subnormal benmineraltetthet

Info

Publication number
NO20022246L
NO20022246L NO20022246A NO20022246A NO20022246L NO 20022246 L NO20022246 L NO 20022246L NO 20022246 A NO20022246 A NO 20022246A NO 20022246 A NO20022246 A NO 20022246A NO 20022246 L NO20022246 L NO 20022246L
Authority
NO
Norway
Prior art keywords
treatment
bone mineral
mineral density
individual
agent
Prior art date
Application number
NO20022246A
Other languages
English (en)
Norwegian (no)
Other versions
NO20022246D0 (no
Inventor
Kenneth E Schwartz
Original Assignee
Genelabs Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genelabs Tech Inc filed Critical Genelabs Tech Inc
Publication of NO20022246D0 publication Critical patent/NO20022246D0/no
Publication of NO20022246L publication Critical patent/NO20022246L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20022246A 1999-11-12 2002-05-10 Behandling av subnormal benmineraltetthet NO20022246L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16508999P 1999-11-12 1999-11-12
US09/710,729 US6605591B1 (en) 1999-11-12 2000-11-10 Treatment of subnormal bone mineral density
PCT/US2000/030131 WO2001035975A2 (en) 1999-11-12 2000-11-13 Treatment of subnormal bone mineral density

Publications (2)

Publication Number Publication Date
NO20022246D0 NO20022246D0 (no) 2002-05-10
NO20022246L true NO20022246L (no) 2002-07-03

Family

ID=26861107

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022246A NO20022246L (no) 1999-11-12 2002-05-10 Behandling av subnormal benmineraltetthet

Country Status (16)

Country Link
US (3) US6605591B1 (de)
EP (1) EP1231983B1 (de)
JP (1) JP2003514026A (de)
KR (1) KR20020063183A (de)
CN (1) CN1411386A (de)
AT (1) ATE326265T1 (de)
AU (1) AU784160B2 (de)
BR (1) BR0015534A (de)
CA (1) CA2390431A1 (de)
DE (1) DE60028074D1 (de)
IL (1) IL149532A0 (de)
MX (1) MXPA02004776A (de)
NO (1) NO20022246L (de)
NZ (1) NZ518791A (de)
RU (1) RU2002115815A (de)
WO (1) WO2001035975A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605591B1 (en) * 1999-11-12 2003-08-12 Genelabs Technologies, Inc. Treatment of subnormal bone mineral density
US8639009B2 (en) 2000-10-11 2014-01-28 Imatx, Inc. Methods and devices for evaluating and treating a bone condition based on x-ray image analysis
US7660453B2 (en) 2000-10-11 2010-02-09 Imaging Therapeutics, Inc. Methods and devices for analysis of x-ray images
CA2446296A1 (en) 2001-05-25 2002-12-05 Imaging Therapeutics, Inc. Methods to diagnose treat and prevent bone loss
US8965075B2 (en) * 2002-09-16 2015-02-24 Imatx, Inc. System and method for predicting future fractures
US7840247B2 (en) * 2002-09-16 2010-11-23 Imatx, Inc. Methods of predicting musculoskeletal disease
CA2519187A1 (en) 2003-03-25 2004-10-14 Imaging Therapeutics, Inc. Methods for the compensation of imaging technique in the processing of radiographic images
US20050014734A1 (en) * 2003-07-18 2005-01-20 Genovate Biotechnology Co., Ltd. Modulation of interleukin-10 by DHEA
CA2580726A1 (en) * 2004-09-16 2006-03-30 Imaging Therapeutics, Inc. System and method of predicting future fractures
EP2061376A2 (de) * 2006-09-15 2009-05-27 Imaging Therapeutics, Inc. Verfahren und system zur bereitstellung einer bruch/nichtbruch-klassifizierung
WO2009019307A2 (en) * 2007-08-09 2009-02-12 Novartis Ag Oral calcitonin compositions and applications thereof
US8999962B2 (en) * 2008-06-03 2015-04-07 John Ray Biffin Method for increasing bone density and/or reducing any osteochondral defects in an animal and a composition including vitamin K
US8939917B2 (en) 2009-02-13 2015-01-27 Imatx, Inc. Methods and devices for quantitative analysis of bone and cartilage

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175146A (en) 1989-12-05 1992-12-29 Vical, Inc. Synthetic calcitonin peptides
WO1994008589A1 (en) 1992-10-09 1994-04-28 The Board Of Trustees Of The Leland Stanford Junior University Treatment of systemic lupus erythematosus with dehydroepiandrosterone
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
WO1998023274A1 (en) 1996-11-25 1998-06-04 Merck & Co., Inc. Androgenic and bisphosphonic agents coadministered to treat diseases
NZ336924A (en) * 1997-02-13 2001-06-29 Bone Care Int Inc Targeted therapeutic delivery of vitamin D compounds via a Vitamin D conjugate
US7045513B1 (en) 1999-03-18 2006-05-16 Genelabs Technologies, Inc. DHEA composition and method
CA2332767A1 (en) 1999-03-18 2000-09-21 Genelabs Technologies, Inc. Dhea composition and method
US6605591B1 (en) * 1999-11-12 2003-08-12 Genelabs Technologies, Inc. Treatment of subnormal bone mineral density

Also Published As

Publication number Publication date
AU1580201A (en) 2001-05-30
AU784160B2 (en) 2006-02-16
ATE326265T1 (de) 2006-06-15
US7612034B2 (en) 2009-11-03
EP1231983A2 (de) 2002-08-21
DE60028074D1 (de) 2006-06-22
KR20020063183A (ko) 2002-08-01
US20050113301A1 (en) 2005-05-26
RU2002115815A (ru) 2004-02-27
WO2001035975A2 (en) 2001-05-25
WO2001035975A3 (en) 2001-12-27
JP2003514026A (ja) 2003-04-15
NZ518791A (en) 2004-03-26
US6854468B2 (en) 2005-02-15
US6605591B1 (en) 2003-08-12
MXPA02004776A (es) 2003-01-28
EP1231983B1 (de) 2006-05-17
CA2390431A1 (en) 2001-05-25
BR0015534A (pt) 2002-07-02
CN1411386A (zh) 2003-04-16
US20030158159A1 (en) 2003-08-21
IL149532A0 (en) 2002-11-10
NO20022246D0 (no) 2002-05-10

Similar Documents

Publication Publication Date Title
NO20022246D0 (no) Behandling av subnormal benmineraltetthet
DK0880350T3 (da) Behandling af dissemineret sklerose
ATE293883T1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
PL332413A1 (en) Compositions containing inhibitors of naaladase as well as methods of treating glutamatic anomaly and influencing neuronic functions among animals
AU4098997A (en) Ammonium siloxane emulsions and their use as fiber treatment agents
PL336788A1 (en) Probucol monoesters in treating circulatory system and inflammatory diseases
BG105534A (en) 5ht1 means and method for the treatment of migraine
ATE320803T1 (de) Verfahren zur behandlung von alzheimerschen krankheit
BR9708362A (pt) Utilização de uma quantidade eficaz de um extrato e processo de tratamento cosmético
ATE240115T1 (de) Zusammensetzung zur vorbeugung und/oder behandlung der atherosklerose
BR9811780A (pt) Método de aumento de volume ósseo usando agonistas seletivos fp não ocorrendo naturalmente
AU5774699A (en) Human stearoyl-coa desaturase-related compositions and methods for treating skin disorders
AUPP674898A0 (en) A method of treatment
MY117918A (en) Use of an h+, k+- atpase inhibitor in the treatment of nasal polyps
HUP0101528A3 (en) The treatment of fertility disorders use of lhrh antagonists and antioestrogens in
GB2331301C (en) Galanin
ZA955782B (en) Heterocycle-condensed morphinoid derivatives
ZA981781B (en) The use of levobupivacaine in treating migraine
WO2000066098A3 (en) Vitamin d derivatives for the treatment of systemic lupus erythematosus
EP0350604A3 (de) Faserbehandlungszusammensetzung
HUP9900007A2 (hu) Készítmény baromfialom kezelésére
WO2000037067A3 (en) Sensitizing agents for the treatment of skin lesions
BA98363A (bs) Postupak i uredaj za tretiranje koze i tome slicno
NO984196L (no) FremgangsmÕte for behandling av stoffmisbruk
ATE282398T1 (de) Verfahren zum dauerwellen von menschlichen haaren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application